HomeHealthcare & Life SciencesPharmaceuticals Myasthenia Gravis Treatment Market

Turkey Myasthenia Gravis Treatment Market Size & Outlook, 2025-2033


Turkey Myasthenia Gravis Treatment Market Insights

  • Based on Reed Intelligence findings, the Turkey Myasthenia Gravis Treatment Market reached USD 15.35 Million in 2024 and is estimated to attain USD 37.3 Million by 2033.
  • From 2026 to 2033, the Turkey market is expected to grow at a steady CAGR of 10.45%.
  • Within the By Type category, Ocular MG  dominated in 2024 in terms of market size contribution.
  • Over the forecast period, Transient Neonatal MG is forecasted to deliver the fastest growth, positioning it as the most lucrative By Type segment.

Other Key Findings


  • Turkey contributed 0.73% to the global Myasthenia Gravis Treatment Market size in 2024.
  • By 2033, United States is forecasted to remain the largest global market for Myasthenia Gravis Treatment Market.
  • In Middle East and Africa, United Arab Emirates is projected to capture the leading share of market size by 2033.
  • Among Middle East and Africa markets, United Arab Emirates is expected to post the fastest growth, reaching USD 232.23 Million by 2033.

Report Summary

Report Scope Details
Base Year for Study 2024
Study Period 2021-2033
Historical Period 2021-2023
Forecast Period 2025-2033
Market Size In 2024 USD 15.35 Million
Market Size In 2033 USD 37.3 Million
Largest segment Ocular MG 
Units Revenue in USD Million
CAGR 10.45% (2025-2033)
Segmnetation Covered
By Type
  1. Ocular MG 
  2. Congenital MG 
  3. Transient Neonatal MG
By Treatment
  1. Medication 
  2. Surgery 
  3. Autologous Hematopoietic Stem Cell Transplantation (HSCT) 
  4. Plasmapheresis and Intravenous Immunoglobulin 
  5. Others
By End-User
  1. Hospitals 
  2. Clinics 
  3. Academic Research Institutes 
  4. Others
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Related Reports